ESGVH (ESCMID Study Group for Viral Hepatitis)

@esgvh.bsky.social

ESGVH is ESCMID's Study Group for Viral Hepatitis. Committed to collaborative excellence in the field of viral hepatitis.

Chronic liver disease can be destabilised by #influenza and other respiratory infections. Honored that our #ESGVH Chair, Prof. @oana-sandulescu.bsky.social joins the #ESWI Board to connect liver health, vaccination and respiratory prevention. @escmid.bsky.social @eswinfluenza.bsky.social

ESWI@eswinfluenza.bsky.social · 2w ago

The #ESWI #Fluzine is back! 🔔 In September's edition: new Coalition Partner & ESWI Associate Members, ESWI #WOHC2026 session recordings, #IDC update - and more. Read the full newsletter here 👉 mailchi.mp/eswi/fluzine... and subscribe at ESWI.org! #Influenza #EUHealth #PublicHealth

Truly honored to join #ESWI and to be part of such an exceptional group of board members&experts. Looking forward to contributing my expertise and exchanging ideas to advance influenza science and public health. Grateful for the opportunity. Excited for the work ahead. @eswinfluenza.bsky.social

ESWI@eswinfluenza.bsky.social · 2w ago

The #ESWI #Fluzine is back! 🔔 In September's edition: new Coalition Partner & ESWI Associate Members, ESWI #WOHC2026 session recordings, #IDC update - and more. Read the full newsletter here 👉 mailchi.mp/eswi/fluzine... and subscribe at ESWI.org! #Influenza #EUHealth #PublicHealth

No one should die from a disease that is preventable, diagnosable and treatable. Yet around 5M people in Europe live with chronic hepatitis B or C, and almost 60,000 people die each year from liver disease linked to these infections. More information about the situation: bit.ly/WorldHepDay2026

World Hepatitis Day 2026: Despite progress towards eliminating hepatitis in Europe, gaps in prevention measures keep 2030 targets out of reach

While Europe has made steady progress in preventing hepatitis B and C the region is set to miss the 2030 target to eliminate viral hepatitis as a public health threat.

bit.ly